Literature DB >> 8218326

Optimization of the retention properties of vincristine in liposomal systems.

N L Boman1, L D Mayer, P R Cullis.   

Abstract

The influence of lipid composition, internal pH and internal buffering capacity on the retention properties of vincristine loaded into large unilamellar vesicle (LUV) systems in response to transmembrane pH gradients has been assessed. It is shown that increasing the (saturated) acyl chain length of the phosphatidylcholine molecule, increasing the internal buffering capacity, and decreasing the internal pH all result in increased drug retention. Further, a study of the pH dependence on the rates of accumulation indicate that uptake proceeds via the neutral form of the vincristine molecule. This uptake is associated with an activation energy of 37 kcal/mol for DSPC/Chol LUVs. It is shown that the major improvement in drug retention in vitro is achieved by employing low initial internal pH values, where 90% retention is obtained over 24 h for an initial internal pH of 2. Improved retention in vivo was also observed where a drug-to-lipid ratio approx. 4-fold greater at 24 h was maintained.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8218326     DOI: 10.1016/0005-2736(93)90256-y

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs.

Authors:  D N Waterhouse; N Dos Santos; L D Mayer; M B Bally
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Lipid nanoparticle delivery systems for siRNA-based therapeutics.

Authors:  C Wan; T M Allen; P R Cullis
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

3.  Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug.

Authors:  Wenli Zhang; Guangji Wang; James R Falconer; Bruce C Baguley; John P Shaw; Jianping Liu; Hongtao Xu; Esther See; Jianguo Sun; Jiye Aa; Zimei Wu
Journal:  Pharm Res       Date:  2014-10-30       Impact factor: 4.200

4.  Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.

Authors:  Deborah A Thomas; Hagop M Kantarjian; Wendy Stock; Leonard T Heffner; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; William Wierda; Sherry Pierce; Biao Lu; Steven R Deitcher; Susan O'Brien
Journal:  Cancer       Date:  2009-12-01       Impact factor: 6.860

5.  Multiseed liposomal drug delivery system using micelle gradient as driving force to improve amphiphilic drug retention and its anti-tumor efficacy.

Authors:  Wenli Zhang; Caibin Li; Ya Jin; Xinyue Liu; Zhiyu Wang; John P Shaw; Bruce C Baguley; Zimei Wu; Jianping Liu
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 6.  Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.

Authors:  Jeffrey A Silverman; Steven R Deitcher
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-05       Impact factor: 3.333

Review 7.  Vincristine sulfate liposomal injection for acute lymphoblastic leukemia.

Authors:  Trisha A Soosay Raj; Amanda M Smith; Andrew S Moore
Journal:  Int J Nanomedicine       Date:  2013-11-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.